Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Comparing mRNA expression between carrier treated and sorafenib treated Myc/NrasG12V liver tumors

ABSTRACT: Comparing mRNA expression between carrier treated and sorafenib treated Myc/NrasG12V liver tumors

PROVIDER: PRJNA681522 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR13165871.fastq.gz	Fastqsanger.gz
	SRR13165872.fastq.gz	Fastqsanger.gz
	SRR13165873.fastq.gz	Fastqsanger.gz
	SRR13165874.fastq.gz	Fastqsanger.gz
	SRR13165875.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

Comparing mRNA expression between carrier treated and sorafenib treated Myc/NrasG12V liver tumors

Project description:To profile determinants of sensitivity and resistance towards the multikinase inhibitor sorafenib in liver cancer (HCC), we generated HCCs with elevated MYC expression and activated Raf-MEK-ERK signaling. To trigger tumor development, we co-delivered transposable elements encoding for Myc and oncogenic NrasG12V via hydrodynamic injection into the hepatocytes of C57BL/6 wildtype mice. To characterize the response of Myc/NrasG12V HCCs towards sorafenib, we analyzed their transcriptomes after three weeks of sorafenib or carrier treatment.

2020-12-01 | GSE162322 | GEO

PLC-PRF-5 cells treated with sorafenib, sorafenib probe or DMSO

Project description:We used an expression profiling chip to detect the expression profile of PLC cells after they were treated with sorafenib and sorafenib probe

2018-12-12 | GSE123600 | GEO

PLC-PRF-5 cells treated with sorafenib, sorafenib probe or DMSO

Project description:PLC-PRF-5 cells treated with sorafenib, sorafenib probe or DMSO

| PRJNA509351 | ENA

Proteomics analysis in DIA mode of 24 weeks from the sorafenib treated and vehicle treated monkeys

Project description:Quantitative proteomics in DIA mode was used to analysis the proteomic profile of 24 weeks from the sorafenib treated and vehicle treated monkeys.

2022-08-30 | PXD018256 | Pride

Comparing mRNA expression of Myc/NrasG12V and Myc/Akt1 driven liver tumors

Project description:Comparing mRNA expression of Myc/NrasG12V and Myc/Akt1 driven liver tumors

| PRJNA681524 | ENA

Comparing mRNA expression of Myc/NrasG12V and Myc/Akt1 driven liver tumors

Project description:To analyze mRNA expression of Myc/NrasG12V and Myc/Akt1 driven liver tumors (HCC), we generated HCCs with elevated MYC expression and activated Raf-MEK-ERK or Akt1 signaling. To trigger tumor development, we co-delivered transposable elements encoding for Myc and oncogenic NrasG12V or myristoylated Akt1 via hydrodynamic injection into the hepatocytes of C57BL/6 wildtype mice and analyzed the transcriptomes of the developed tumors.

2020-12-01 | GSE162324 | GEO

PCR array screening for gene expression changes in HCC model comparing sorafenib treated or control samples

Project description:Candidate genes were successfully screened by Cancer PathwayFinder PCR Array Cancer PathwayFinder PCR Array was applied to compare gene changes in xenograft tumor samples of HCC model. A total of 12 samples were examined with 6 from Sorafenib treated group and 6 from control.

2011-11-11 | E-GEOD-33621 | biostudies-arrayexpress

Total RNAseq of HepG2 cells treated with Sorafenib

Project description:Hepatocellular carcinoma (HCC) is one of the most common causes of death worldwide and the fourth most prevalent type of cancer. Whereas curative treatments such as liver transplantation, ablation or surgery are optimal for early stages, only paliative treatments are given to intermediate and advanced stages of the disease. Sorafenib is still a suitable therapeutic option for patients in whom immunotherapy is not feasible. To gain information about therapy response, we sequenced HepG2 cells treated with Sorafenib 10 µM (24 hours)

2023-12-01 | GSE225537 | GEO

Whole genome profiling of whole liver lysates of vehicle and Sorafenib-treated iAST mice

Project description:Analysis of changes in gene expression upon Sorafenib treatment. Looking for candidates, that could potentially be up- or down-regulated upon Sorefanib treatment. Total RNA were optained from whole liver lysates of vehicle 14d-, Sorafenib 14d- and LT Sorafenib-treated iAST mice

2014-06-20 | E-GEOD-54857 | biostudies-arrayexpress

Transcriptome analysis of zebrafish heart exposed to sorafenib

Project description:Sorafenib is associated with cardiac adverse effects, including left ventricular dysfunction. However, the precise mechanism remains unclear. Here, we aimed to establish the genes responsible for this cardiotoxicity using zebrafish. A pigmentless zebrafish line expressing green fluorescent protein in the heart were treated with or without sorafenib. In vivo fluorescent cardiac imaging revealed that the ventricular dimension of the longitudinal axis in zebrafish treated with sorafenib was significantly lower than in those without sorafenib. Transcriptome analysis of zebrafish hearts revealed that expression of stanniocalcin1 (stc1) in zebrafish treated with sorafenib was significantly lower than that without sorafenib treatment. We were able to demonstrate that the ventricular dimension of the longitudinal axis in stc1 morphant was significantly smaller than that of control zebrafish and that forced expression of stc1 normalized the decrease in ventricular diameter in stc1 morphant and zebrafish treated with sorafenib. These data suggest that stc1 is the gene responsible for sorafenib-induced cardiotoxicity.

2014-12-04 | GSE61155 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data